Bradly M. Bauman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bradly M. Bauman has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Andrew L. Snow
Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
4 shared publications - Tao‐Yiao John Wu
Department of Gynecologic Surgery and Obstetrics Uniformed Services University of the Health Sciences Bethesda Maryland USA
4 shared publications Andrew L. Snow
Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2 shared publications- Ashley L. Russell
Department of Physical Medicine and Rehabilitation, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
2 shared publications Batsukh Dorjbal
Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, 20817, USA
2 shared publicationsKelsey Voss
Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, USA
2 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Functional validation of PIK3R1 variant causing activated phosphoinositide 3-kinase-δ syndrome 2 with hypogammaglobulinemia and bronchiectasis
A heterozygous PIK3R1 variant (c.1300-2A>G) was identified in a patient with hypogammaglobulinemia and bronchiectasis. Functional validation revealed aberrant lymphocyte cell states, confirming activated phosphoinositide 3-kinase-δ syndrome 2 and supporting targeted treatment. This work reinforces the importance of precise genetic diagnosis in primary immunodeficiencies.
- 13 August 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Open AccessFunctional validation of PIK3R1 variant causing activated phosphoinositide 3-kinase-δ syndrome 2 with hypogammaglobulinemia and bronchiectasis
A heterozygous PIK3R1 variant (c.1300-2A>G) was identified in a patient with hypogammaglobulinemia and bronchiectasis. Functional validation revealed aberrant lymphocyte cell states, confirming activated phosphoinositide 3-kinase-δ syndrome 2 and supporting targeted treatment. This work reinforces the importance of precise genetic diagnosis in primary immunodeficiencies.
- 20 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (6)
Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells
Several “primary atopic disorders” are linked to monogenic defects that attenuate TCR signaling, favoring T helper type 2 (TH2) cell differentiation. Patients with CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS) disease suffer from severe atopy, caused by germline loss-of-function/dominant interfering (LOF/DI) CARD11 variants. The CARD11 scaffold enables TCR-induced activation of NF-κB, mTORC1, and JNK signaling, yet the function of CARD11-dependent JNK signaling in T cells remains nebulous. Here we show that CARD11 is critical for TCR-induced activation of JNK1 and JNK2, as well as canonical JUN/FOS AP-1 family members. Patient-derived CARD11 DI variants attenuated WT CARD11 JNK signaling, mirroring effects on NF-κB. Transcriptome profiling revealed JNK inhibition upregulated TCR-induced expression of GATA3 and NFATC1, key transcription factors for TH2 cell development. Further, impaired CARD11-JNK signaling was linked to enhanced GATA3 expression in CADINS patient T cells. Our findings reveal a novel intrinsic mechanism connecting impaired CARD11-dependent JNK signaling to enhanced GATA3/NFAT2 induction and TH2 cell differentiation in CADINS patients.
- 20 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (6)
Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells
Several “primary atopic disorders” are linked to monogenic defects that attenuate TCR signaling, favoring T helper type 2 (TH2) cell differentiation. Patients with CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS) disease suffer from severe atopy, caused by germline loss-of-function/dominant interfering (LOF/DI) CARD11 variants. The CARD11 scaffold enables TCR-induced activation of NF-κB, mTORC1, and JNK signaling, yet the function of CARD11-dependent JNK signaling in T cells remains nebulous. Here we show that CARD11 is critical for TCR-induced activation of JNK1 and JNK2, as well as canonical JUN/FOS AP-1 family members. Patient-derived CARD11 DI variants attenuated WT CARD11 JNK signaling, mirroring effects on NF-κB. Transcriptome profiling revealed JNK inhibition upregulated TCR-induced expression of GATA3 and NFATC1, key transcription factors for TH2 cell development. Further, impaired CARD11-JNK signaling was linked to enhanced GATA3 expression in CADINS patient T cells. Our findings reveal a novel intrinsic mechanism connecting impaired CARD11-dependent JNK signaling to enhanced GATA3/NFAT2 induction and TH2 cell differentiation in CADINS patients.
- 2 October 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451245
A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling
A20 is a dual‐function ubiquitin‐editing enzyme that maintains immune homeostasis by restraining inflammation. Although A20 serves a similar negative feedback function for T‐cell receptor (TCR) signaling, the molecular mechanisms utilized and their ultimate impact on human T‐cell function remain unclear. TCR engagement triggers the assembly of the CARD11‐BCL10‐MALT1 (CBM) protein complex, a signaling platform that governs the activation of downstream transcription factors including NF‐κB and c‐Jun/AP‐1. Utilizing WT and A20 knockout Jurkat T cells, we found that A20 is required to negatively regulate NF‐κB and JNK. Utilizing a novel set of A20 mutants in NF‐κB and AP‐1‐driven reporter systems, we discovered the ZnF7 domain is crucial for negative regulatory capacity, while deubiquitinase activity is dispensable. Successful inactivation of A20 in human primary effector T cells congruently conferred sustained NF‐κB and JNK signaling, including enhanced upregulation of activation markers, and increased secretion of several cytokines including IL‐9. Finally, loss of A20 in primary human T cells resulted in decreased sensitivity to restimulation‐induced cell death and increased sensitivity to cytokine withdrawal‐induced death. These findings demonstrate the importance of A20 in maintaining T‐cell homeostasis via negative regulation of both NF‐κB and JNK signaling.
- 2 October 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451245
A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling
A20 is a dual‐function ubiquitin‐editing enzyme that maintains immune homeostasis by restraining inflammation. Although A20 serves a similar negative feedback function for T‐cell receptor (TCR) signaling, the molecular mechanisms utilized and their ultimate impact on human T‐cell function remain unclear. TCR engagement triggers the assembly of the CARD11‐BCL10‐MALT1 (CBM) protein complex, a signaling platform that governs the activation of downstream transcription factors including NF‐κB and c‐Jun/AP‐1. Utilizing WT and A20 knockout Jurkat T cells, we found that A20 is required to negatively regulate NF‐κB and JNK. Utilizing a novel set of A20 mutants in NF‐κB and AP‐1‐driven reporter systems, we discovered the ZnF7 domain is crucial for negative regulatory capacity, while deubiquitinase activity is dispensable. Successful inactivation of A20 in human primary effector T cells congruently conferred sustained NF‐κB and JNK signaling, including enhanced upregulation of activation markers, and increased secretion of several cytokines including IL‐9. Finally, loss of A20 in primary human T cells resulted in decreased sensitivity to restimulation‐induced cell death and increased sensitivity to cytokine withdrawal‐induced death. These findings demonstrate the importance of A20 in maintaining T‐cell homeostasis via negative regulation of both NF‐κB and JNK signaling.
- Open Access
- 14 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (4) , 1-17
TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1
Immune homeostasis depends upon effective clearance of pathogens while simultaneously preventing autoimmunity and immunopathology in the host. Restimulation-induced cell death (RICD) is one such mechanism where by activated T cells receive subsequent antigenic stimulation, reach a critical signal threshold through the T cell receptor (TCR), and commit to apoptosis. Many details of this process remain unclear, including the role of co-stimulatory and co-inhibitory proteins that influence the TCR signaling cascade. Here we characterize the role of T cell immunoglobulin and mucin domain containing 3 (TIM-3) in RICD regulation. TIM-3 protected newly activated CD8+ effector T cells from premature RICD during clonal expansion. Surprisingly, however, we found that TIM-3 potentiated RICD in late-stage effector T cells. The presence of TIM-3 increased proximal TCR signaling and proapoptotic protein expression in late-stage effector T cells, with no consistent signaling effects noted in newly activated cells with or without TIM-3. To better explain these differences in TIM-3 function as T cells aged, we characterized the temporal pattern of TIM-3 expression in effector T cells. We found that TIM-3 was expressed on the surface of newly activated effector T cells, but remained largely intracellular in late-stage effector cells. Consistent with this, TIM-3 required a ligand to prevent early RICD, whereas ligand manipulation had no effects at later stages. Of the known TIM-3 ligands, carcinoembryonic antigen‐related cell adhesion molecule (CEACAM1) showed the greatest difference in surface expression over time and also protected newly activated cells from premature RICD, with no measurable effects in late-stage effectors. Indeed, CEACAM1 enabled TIM-3 surface expression on T cells, implying a co-dependency for these proteins in protecting expanding T cells from premature RICD. Our findings suggest that co-signaling proteins like TIM-3 and CEACAM1 can alter RICD sensitivity at different stages of the effector T cell response, with important implications for checkpoint blockade therapy.
- 14 April 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (4) , 1-17
Open AccessTIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1
Immune homeostasis depends upon effective clearance of pathogens while simultaneously preventing autoimmunity and immunopathology in the host. Restimulation-induced cell death (RICD) is one such mechanism where by activated T cells receive subsequent antigenic stimulation, reach a critical signal threshold through the T cell receptor (TCR), and commit to apoptosis. Many details of this process remain unclear, including the role of co-stimulatory and co-inhibitory proteins that influence the TCR signaling cascade. Here we characterize the role of T cell immunoglobulin and mucin domain containing 3 (TIM-3) in RICD regulation. TIM-3 protected newly activated CD8+ effector T cells from premature RICD during clonal expansion. Surprisingly, however, we found that TIM-3 potentiated RICD in late-stage effector T cells. The presence of TIM-3 increased proximal TCR signaling and proapoptotic protein expression in late-stage effector T cells, with no consistent signaling effects noted in newly activated cells with or without TIM-3. To better explain these differences in TIM-3 function as T cells aged, we characterized the temporal pattern of TIM-3 expression in effector T cells. We found that TIM-3 was expressed on the surface of newly activated effector T cells, but remained largely intracellular in late-stage effector cells. Consistent with this, TIM-3 required a ligand to prevent early RICD, whereas ligand manipulation had no effects at later stages. Of the known TIM-3 ligands, carcinoembryonic antigen‐related cell adhesion molecule (CEACAM1) showed the greatest difference in surface expression over time and also protected newly activated cells from premature RICD, with no measurable effects in late-stage effectors. Indeed, CEACAM1 enabled TIM-3 surface expression on T cells, implying a co-dependency for these proteins in protecting expanding T cells from premature RICD. Our findings suggest that co-signaling proteins like TIM-3 and CEACAM1 can alter RICD sensitivity at different stages of the effector T cell response, with important implications for checkpoint blockade therapy.
- 2 January 2020
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (2) , 406-411
A Novel, Heterozygous Three Base-Pair Deletion in CARD11 Results in B Cell Expansion with NF-κB and T Cell Anergy Disease
Germline gain-of-function mutations in CARD11 lead to the primary immunodeficiency, B cell expansion with NF-κB, and T cell anergy (BENTA). Herein, we report the case of a girl, presenting at 2 years of age with lymphocytosis and splenomegaly in whom a novel, in-frame, three base pair deletion in CARD11 was identified resulting in the deletion of a single lysine residue (K215del) from the coiled-coil domain. In vitro functional assays demonstrated that this variant leads to a subtle increase in baseline NF-κB signaling and impaired proliferative responses following T cell receptor and mitogenic stimulation. Previously reported immunological defects associated with BENTA appear mild in our patient who is now 6 years of age; a B cell lymphocytosis and susceptibility to upper respiratory tract infections persist; however, she has broad, sustained responses to protein-polysaccharide conjugate vaccines and displays normal proliferative responses to ex vivo T cell stimulation.
- 2 January 2020
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (2) , 406-411
A Novel, Heterozygous Three Base-Pair Deletion in CARD11 Results in B Cell Expansion with NF-κB and T Cell Anergy Disease
Germline gain-of-function mutations in CARD11 lead to the primary immunodeficiency, B cell expansion with NF-κB, and T cell anergy (BENTA). Herein, we report the case of a girl, presenting at 2 years of age with lymphocytosis and splenomegaly in whom a novel, in-frame, three base pair deletion in CARD11 was identified resulting in the deletion of a single lysine residue (K215del) from the coiled-coil domain. In vitro functional assays demonstrated that this variant leads to a subtle increase in baseline NF-κB signaling and impaired proliferative responses following T cell receptor and mitogenic stimulation. Previously reported immunological defects associated with BENTA appear mild in our patient who is now 6 years of age; a B cell lymphocytosis and susceptibility to upper respiratory tract infections persist; however, she has broad, sustained responses to protein-polysaccharide conjugate vaccines and displays normal proliferative responses to ex vivo T cell stimulation.
- 28 October 2019
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 18 (1) , 194-205
FOXP3 protects conventional human T cells from premature restimulation-induced cell death
The adaptive immune response relies on specific apoptotic programs to maintain homeostasis. Conventional effector T cell (Tcon) expansion is constrained by both forkhead box P3 (FOXP3)+-regulatory T cells (Tregs) and restimulation-induced cell death (RICD), a propriocidal apoptosis pathway triggered by repeated stimulation through the T-cell receptor (TCR). Constitutive FOXP3 expression protects Tregs from RICD by suppressing SLAM-associated protein (SAP), a key adaptor protein that amplifies TCR signaling strength. The role of transient FOXP3 induction in activated human CD4 and CD8 Tcons remains unresolved, but its expression is inversely correlated with acquired RICD sensitivity. Here, we describe a novel role for FOXP3 in protecting human Tcons from premature RICD during expansion. Unlike FOXP3-mediated protection from RICD in Tregs, FOXP3 protects Tcons through a distinct mechanism requiring de novo transcription that does not require SAP suppression. Transcriptome profiling and functional analyses of expanding Tcons revealed that FOXP3 enhances expression of the SLAM family receptor CD48, which in turn sustains basal autophagy and suppresses pro-apoptotic p53 signaling. Both CD48 and FOXP3 expression reduced p53 accumulation upon TCR restimulation. Furthermore, silencing FOXP3 expression or blocking CD48 decreased the mitochondrial membrane potential in expanding Tcons with a concomitant reduction in basal autophagy. Our findings suggest that FOXP3 governs a distinct transcriptional program in early-stage effector Tcons that maintains RICD resistance via CD48-dependent protective autophagy and p53 suppression.
- 28 October 2019
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 18 (1) , 194-205
FOXP3 protects conventional human T cells from premature restimulation-induced cell death
The adaptive immune response relies on specific apoptotic programs to maintain homeostasis. Conventional effector T cell (Tcon) expansion is constrained by both forkhead box P3 (FOXP3)+-regulatory T cells (Tregs) and restimulation-induced cell death (RICD), a propriocidal apoptosis pathway triggered by repeated stimulation through the T-cell receptor (TCR). Constitutive FOXP3 expression protects Tregs from RICD by suppressing SLAM-associated protein (SAP), a key adaptor protein that amplifies TCR signaling strength. The role of transient FOXP3 induction in activated human CD4 and CD8 Tcons remains unresolved, but its expression is inversely correlated with acquired RICD sensitivity. Here, we describe a novel role for FOXP3 in protecting human Tcons from premature RICD during expansion. Unlike FOXP3-mediated protection from RICD in Tregs, FOXP3 protects Tcons through a distinct mechanism requiring de novo transcription that does not require SAP suppression. Transcriptome profiling and functional analyses of expanding Tcons revealed that FOXP3 enhances expression of the SLAM family receptor CD48, which in turn sustains basal autophagy and suppresses pro-apoptotic p53 signaling. Both CD48 and FOXP3 expression reduced p53 accumulation upon TCR restimulation. Furthermore, silencing FOXP3 expression or blocking CD48 decreased the mitochondrial membrane potential in expanding Tcons with a concomitant reduction in basal autophagy. Our findings suggest that FOXP3 governs a distinct transcriptional program in early-stage effector Tcons that maintains RICD resistance via CD48-dependent protective autophagy and p53 suppression.
- 1 May 2019
- Published by Elsevier in Neuroscience
- Vol. 406, 268-277
Isoflavones Alter Hypothalamic–Pituitary–Adrenal Axis Response Following Photoperiod Alteration
- 1 May 2019
- Published by Elsevier in Neuroscience
- Vol. 406, 268-277
Isoflavones Alter Hypothalamic–Pituitary–Adrenal Axis Response Following Photoperiod Alteration
- Open Access
- 19 September 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2078
The CBM-opathies—A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex
The caspase recruitment domain family member 11 (CARD11 or CARMA1)—B cell CLL/lymphoma 10 (BCL10)—MALT1 paracaspase (MALT1) [CBM] signalosome complex serves as a molecular bridge between cell surface antigen receptor signaling and the activation of the NF-κB, JNK, and mTORC1 signaling axes. This positions the CBM complex as a critical regulator of lymphocyte activation, proliferation, survival, and metabolism. Inborn errors in each of the CBM components have now been linked to a diverse group of human primary immunodeficiency diseases termed “CBM-opathies.” Clinical manifestations range from severe combined immunodeficiency to selective B cell lymphocytosis, atopic disease, and specific humoral defects. This surprisingly broad spectrum of phenotypes underscores the importance of “tuning” CBM signaling to preserve immune homeostasis. Here, we review the distinct clinical and immunological phenotypes associated with human CBM complex mutations and introduce new avenues for targeted therapeutic intervention.
- 19 September 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 2078
Open AccessThe CBM-opathies—A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex
The caspase recruitment domain family member 11 (CARD11 or CARMA1)—B cell CLL/lymphoma 10 (BCL10)—MALT1 paracaspase (MALT1) [CBM] signalosome complex serves as a molecular bridge between cell surface antigen receptor signaling and the activation of the NF-κB, JNK, and mTORC1 signaling axes. This positions the CBM complex as a critical regulator of lymphocyte activation, proliferation, survival, and metabolism. Inborn errors in each of the CBM components have now been linked to a diverse group of human primary immunodeficiency diseases termed “CBM-opathies.” Clinical manifestations range from severe combined immunodeficiency to selective B cell lymphocytosis, atopic disease, and specific humoral defects. This surprisingly broad spectrum of phenotypes underscores the importance of “tuning” CBM signaling to preserve immune homeostasis. Here, we review the distinct clinical and immunological phenotypes associated with human CBM complex mutations and introduce new avenues for targeted therapeutic intervention.
- 25 April 2018
- Published by The Endocrine Society in Endocrinology
- Vol. 159 (6) , 2363-2375
Differential Responses of the HPA Axis to Mild Blast Traumatic Brain Injury in Male and Female Mice
Traumatic brain injury (TBI) affects 10 million people world-wide, annually. TBI is linked to increased risk of psychiatric disorders. TBI induced by explosive devices has a unique phenotype. Over 1/3 of people exposed to blast-induced (b)TBI have prolonged neuroendocrine deficits, shown by anterior pituitary dysfunction. Dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis is linked to increased risk for psychiatric disorders. Not only is there limited information on how the HPA axis responds to mild (m)bTBI, sex differences are understudied. We examined central and peripheral HPA axis reactivity 7-10 days after mbTBI in male and female mice. Males exposed to mbTBI had increased restraint-induced serum corticosterone (CORT), but attenuated restraint-induced corticotropin-releasing factor (CRF)/c-FOS-immunoreactivity (ir) in the paraventricular nucleus of the hypothalamus (PVN). Females displayed an opposite response, with attenuated restraint-induced CORT and enhanced restraint-induced PVN CRF/c-FOS-ir. We examined potential mechanisms underlying this dysregulation and found that mbTBI did not affect pituitary (POMC, CRFR1) or adrenal (11β-OHase, 11β-HSD1 and Mc2R) gene expression. mbTBI did not alter MR or GR gene expression in the PVN or relevant limbic structures. In females, but not males, mbTBI decreased c-FOS-ir in non-neuroendocrine (presumably pre-autonomic) CRF neurons in the PVN. While we demonstrated a sex-dependent link to stress dysregulation of pre-autonomic neurons in females, we hypothesize that mbTBI may disrupt limbic pathways involved in HPA axis coordination in males. Overall, mbTBI altered the HPA axis in a sex-dependent manner, highlighting the importance of developing therapies to target individual strategies that males and females utilize to cope with mbTBI.
- 25 April 2018
- Published by The Endocrine Society in Endocrinology
- Vol. 159 (6) , 2363-2375
Differential Responses of the HPA Axis to Mild Blast Traumatic Brain Injury in Male and Female Mice
Traumatic brain injury (TBI) affects 10 million people world-wide, annually. TBI is linked to increased risk of psychiatric disorders. TBI induced by explosive devices has a unique phenotype. Over 1/3 of people exposed to blast-induced (b)TBI have prolonged neuroendocrine deficits, shown by anterior pituitary dysfunction. Dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis is linked to increased risk for psychiatric disorders. Not only is there limited information on how the HPA axis responds to mild (m)bTBI, sex differences are understudied. We examined central and peripheral HPA axis reactivity 7-10 days after mbTBI in male and female mice. Males exposed to mbTBI had increased restraint-induced serum corticosterone (CORT), but attenuated restraint-induced corticotropin-releasing factor (CRF)/c-FOS-immunoreactivity (ir) in the paraventricular nucleus of the hypothalamus (PVN). Females displayed an opposite response, with attenuated restraint-induced CORT and enhanced restraint-induced PVN CRF/c-FOS-ir. We examined potential mechanisms underlying this dysregulation and found that mbTBI did not affect pituitary (POMC, CRFR1) or adrenal (11β-OHase, 11β-HSD1 and Mc2R) gene expression. mbTBI did not alter MR or GR gene expression in the PVN or relevant limbic structures. In females, but not males, mbTBI decreased c-FOS-ir in non-neuroendocrine (presumably pre-autonomic) CRF neurons in the PVN. While we demonstrated a sex-dependent link to stress dysregulation of pre-autonomic neurons in females, we hypothesize that mbTBI may disrupt limbic pathways involved in HPA axis coordination in males. Overall, mbTBI altered the HPA axis in a sex-dependent manner, highlighting the importance of developing therapies to target individual strategies that males and females utilize to cope with mbTBI.